The titre of virus in a dengue patient and the duration of this viraemia has a profound effect on whether or not a mosquito will become infected when it feeds on the patient and this, in turn is a key driver of the magnitude of a dengue outbreak. As mosquitoes require 100-1000 times more virus to become infected than a patient, the transmission of dengue virus from a patient to a mosquito is a vulnerability that may be able to be targeted to improve disease control. The intrinsic variability in the within-host dynamics of viraemias is explored for a population of patients using the method of population of models (POMs). A dataset from 207 patients is used to calibrate 20,000 models for the infection kinetics for each of the four dengue virus serotypes. The effect of adding defective dengue virus interfering particles to patients as a therapeutic is evaluated using the calibrated POMs in a bang-bang optimal control setting.
severity of the associated symptoms [9] . Any process that reduces the initial viraemia in dengue patients might reduce disease 19 severity and also the risk that a mosquito feeding on the patient would become infected and pass the virus to a new host. 20 Populations of DENV include virions with genomes with defects ranging from single nucleotide changes [10] to deletion of 21 more than 90 per cent of the genome [11] . Some of these are transmitted in nature for a year or more [10] . DENV virions 22 containing genomes with extensive deletions interfere with the replication of wild type viruses. This phenomenon has been 23 observed with a large number of viruses, mostly with RNA genomes [12, 13] . Furthermore, it has been possible to demonstrate 24 that virions with defective genomes reduce the yield of virus from cells infected with wild type DENV and are known, 25 therefore, as defective interfering (DI) particles [14] [15] [16] . 26 There is an extensive literature on the activity of DI particles across a wide range of RNA viruses but interest waned in 27 the 1990s [13, 17] . With the advent of tools to better define DI genomes and to produce artificial ones, there has been a 28 renewed interest in their therapeutic potential and the possibility that they could be used to block transmission of agents such 29 as DENV. However current mathematical models of dengue [18] [19] [20] cannot capture all the aspects of virus transmission and 30 no model incorporates defective interfering (DI) particles. A few intracellular, intra-host and population models are available 31 on different infectious diseases such as influenza, scabies, and optimal design for disease control [21] [22] [23] . This study uses data 32 from 207 dengue patients in a real clinical setting [8] in order to estimate the therapeutic potential of DENV DI particles. 33 We propose a model inspired by the Clapham et. al. [19] and Frank [24] models. This model considers the antibody 34 response in viral neutralization and the natural generation of DI particles. We build an ensemble, population, of models, in 35 which each element in the population is a mathematical model with exactly the same framework, but where each model has a 36 different set of parameter values for the same set of parameters. All of these values are calibrated in some appropriate way 37 against multiple data [25] . In particular, we calibrate the data for plasma viral load and antibody response for 207 patients in 38 our population of models (POMs). Most of the patients have high viraemia amplitudes during the illness. However, the 39 antibody data has been collected on two random days within their febrile periods and that cannot explain the exact dynamics 40 of the antibody, even asymptotically. With our POMs, we try to explore the range of variability in different cell-virus 41 interactions and the immune responses. The POMs study is well-known in cardiac electrophysiology models [26, 27] but for 42 infectious diseases, it is the first article to be reported for a large set of patient data. We develop a population of controls 43 (POCs) to the population of symptomatic patients to attenuate the within-host viraemia level and reduce the days of febrile 44 period. Specifically, bang-bang control is used to determine the minimum dose of DI particles which must be delivered to 45 minimise the height and duration of the viraemia. 46 We propose that we can account for the inherent variability in the dengue infected patient data and find a modeling 47 paradigm based on population of models and optimal control that allows us to quantify the effectiveness of DI particles in 48 controlling the viraemia.
49

Materials and methods
50
Within-host viraemia dynamics 51
To explain the novelty of the present model, we must say that the competitive dynamics of the DI particles with virus is 52 exhibited in the presence of the antibody response. While the model of Clapham et al. [19] included the role of antibody 53 response in controlling the levels of viraemia, the model assumed that only standard virus is replicated within the host body. 54 Defective interfering particles may also be responsible for the reduction in the production of standard virus [11, 14] . The dynamics of the present model is given by in the following set of ordinary differential equations
This new model describes the dynamics of standard virus (V) and DI particles (D) within the host. We consider the 57 antibody response (Z) by the infected cells in virus neutralization. The present model is built with very specific aspects of 58 dengue based on the models [17, 19, 24] . The uninfected target cells (C U ) become infected and consequently produce four 59 types of infected cells: infected by DI only (C D ), virus only (C V ), virus-infected and late enough for further infection (C V * ), 60 and infected by both (C V D ) ( Fig 1) . previous models, although the range of their values from the aforesaid papers [19, 24] are informative in creating the 71 population of models. The initial conditions of C U , C D , C V , C V * , C V D and D are considered constant at the start of 72 infection. Only the initial viral load (V 0 ) and antibody levels (Z 0 ) for each patient have been sampled in the population of 73 models. The patient specific parameters (α, δ, η 1 , η 2 , π 1 , π 2 , φ) are sampled using Latin Hypercube sampling (LHS) within the 74 [28] . The way this is done is to discretise a d dimensional parameter space with some mesh and then place 76 a cross in a box such that there is only ever one cross in each d − 1 dimensional subspace. A cross means that box is sampled 77 at random for the d parameter values. The remaining parameters have been classified into two classes: natural human host 78 parameters (r and K), which are constant in the complete POMs, and serotype-specific parameters (β, , γ, k, µ, ρ), which 79 stay constant for a POMs of a particular serotype. We tabulate the description of the rate parameters in Table 1 .
80
Population of models 81
Variability inherently occurs in many biological and physiological measurements and we cannot avoid them. Every patient, for 82 example, may have very different responses to an infection or a treatment and we need to account for this variability.
83
Sometimes we aggregate the data and fit the model to the mean trajectory or choose a subset of the data as being 84 representative or the hypothetically best sets of data and extrapolate those features to the large population. This can reduce 85 the errors in measurement, but is unable to capture the intrinsic variability in the system. Hence, analysing models in a 86 population from a set of measured data and exploring the hidden features intrinsic to the system is more effective for 87 predicting physiological phenomena when there is inherent variability.
88
We use the Data2Dynamics package in Matlab for parameter estimation [29] . We generate multiple candidate models with 89 parameters sampled by Latin Hypercube Sampling. We are at liberty to choose different criteria for our calibration. In 90 original articles we calibrated to the range of the data [27] , but this is somewhat crude. More recently, we proposed 91 calibration based on matching the distributions in the data available [25] . This means that appropriate outputs from the 92 POM matches the data in a distribution setting. In the present article we are following the earlier method as the amount of 93 sampling is very large in the current system. In the first step of calibration, we try to calibrate to the median and other 94 quartiles of the data but we can not fully capture the range of the data sets at the same time. For the whole data-set 95 viraemia and antibody response, we estimate all the parameters and fixed the natural human host parameters (r and K) as 96 constant and the remaining parameters are estimated again for the four different serotypes. The Latin Hypercube sampling is 97 performed for each of the serotypes simultaneously with the serotype-specific parameters (β, , γ, k, µ, ρ) constant. From these 98 population of models, we select only those models that cover the regions and range for all the biomarker results on each day 99 of illness. We generate a very large initial POMs (20000) for each serotype and the calibrated POMs has been constructed by 100 4/16 only those models that can capture the range.
101
Optimal bang-bang control 102 There are two ways of implementing the control. One is continuous and differentiable. The other one is continuous but occurs 103 as a step function and is known as bang-bang control, in which the control is either on or off. In practical settings bang-bang 104 control is more appropriate for intervention and that is what we use here. 105 We follow the algorithmic steps for bang-bang control for a nonlinear system of ODEs as follows 106 (1) Describe the system with the control variable as
(2) Construct the payoff functional in terms of running cost (L) and terminal cost (φ) functional as
where u is the control variable, or vector of control variables, with bounds 0 ≤ u ≤ u b .
109
(3) Construct the Hamiltonian
i.e.,
Here the lambda are the elements of the vector of Lagrange multipliers.
111
(4) From the Pontryagin's minimum principal [30] the switching function is
that determines the bang time (τ ), when the control u(t) is on or off. The particular time points (τ 's) are known as the 113 switching time points.
114
(5) The optimal bang-bang control (u * (t)) flips between the bounds, [0, u b ] at the switching points as
In the present study we use one control variable (u(t)), the administration of excess DI particles to the model to reduce the 116 viral infection as well as quick clearance of the virus from the host. For the present POMs of four dengue serotypes, the range 117 of the viraemia growth is large (approximately 10 3 to 10 11 ). For that reason it is difficult to decide on upper bounds of the 118 control (u b ) for these POMs. We determine the u b from the individual uncontrolled viraemia profile for each model considered 119 to be controlled.
120
Control strategy for dengue fever 121 As the objective to control dengue for the model within host, we construct an objective function in terms of the running cost 122 functional only. The reason is that all the infection and virus naturally get cleared at the final time point and terminal cost is 123 insignificant in such cases.
where T 0 and T f are the initial and final time, and a, b and c are constants to be determined from the optimal control 125 problem. In the course of control, we prefer to apply a bang-bang type control rather than a continuous control. Here, the 126 administration dose rate (u(t)) of DI particles is the control variable. The medical nomenclature of the purified DI particles is 127 therapeutic interfering particles or TIPs. In order to make the vaccination program cost-effective and reduce the time course 128 of the vaccination process this information is included in the structure of the pay off function during the optimization. As the 129 plasma viraemia (V ) and the cellular infection of all kinds (C V , C V * ) show a rapid growth in the first 2-4 days of the febrile 130 5/16
period and are cleared within 10-12 days, we seek to minimize the peak of the viraemia (V ) and virus infected cells (C V ) that 131 in consequence may help reduce all the infections. The DI particles within the host (D) compete with the virus for the 132 uninfected cells (C U ) and that is an advantage to introduce a large number of DI particles to inhibit the viral infection. The 133 system of ODEs can be rewritten after introducing the control variable, u(t) as
We assign bang-bang controls to the models from the POMs discussed above and obtain a population of controls (POCs) between the infection and start of illness are known as the incubation period for the plasma viraemia. For a large population 144 of patients, it is difficult to frame the range of this time period in a dynamical model. To address this problem, we consider 145 that the start of illness is a day in between the day of infection and maximum plasma viral load. The fever starts with a 146 range of detectable viraemia load (V 0 ) on the day the illness starts. Although DI particles are not observed directly in any 147 prior study of blood viraemia trajectories they are known to occur naturally in viral infection systems. We may predict that 148 from our POMs construction as they are generated naturally in viral infection systems. Fig 2 represents the calibrated POMs 149 (black lines) with the reported plasma viraemia (red dots) for each of the four DENV serotypes for 10 days of their febrile 150 periods. In the initial calibrated POMs, we found many viraemia models with large oscillations and abrupt growth in the 151 antibody models. Although they satisfy the criteria to be included in the final POMs, they are omitted from the analysis as 152 we cannot find any oscillatory behaviour in the reported viraemia data.
153
In Fig 2, we present the POMs constructed (in black) based on the available biomarker data (in red). The data for the 154 viraemia are regularly collected for every patients from day 2 to day 8 and that is reflected in the calibrated POMs nicely.
155
But the available data for the antibody response is not that consistent as they appear randomly on any two of the days of 156 illness. Calibration of the POMs for these data does not perform as effectively as for the viraemia population. To analyse the 157 POMs for the four serotypes comparatively, we see that the POMs for DENV-2 is the most tightly calibrated with the In Fig 4, we depict the antibody response with respect to corresponding viraemia levels on every day of illness for further 170 clarification of the calibration process. The black dots are the antibody-viraemia data points calculated from the accepted 171 POMs on each day of illness. We show that most of the POMs results stay within the ranges of the biomarker data on day 3, 172 4, 5, 6 and 7 for all the four serotypes. On days 2 and 8, due to very low number of data-points, the range detection is not a 173 reliable indicator of goodness of fit for the POMs..
174
For each of the patient-specific parameters, which have been allowed to vary in the population, the partial correlation 175 coefficient (PCC) is calculated pairwise with the biomarkers calculated from the POMs. This correlation based approach can 176 explore the sensitivity of the model parameters in association with the parameter variability. The PCC identifies one-to-one 177 correlation between a particular parameter with the specific biomarker after removing the contributions of all the other 178 variables. Thus it magnifies the one-to-one correlation between the parameter-biomarker pair. In Fig 5, we present three 179 different heatmaps to quantitatively compare the PCC levels among the patient-specific parameters and the viraemia load, In row Fig 5A, the PCCs of viraemia with different parameters are plotted. δ shows a transition from highly positive to 184 highly negative correlation as long as the illness continues, while η 1 goes in the opposite direction. However, η 2 is not 185 following a similar trend across the serotypes. To classify the PCCs for η 2 , DENV-1 and 3 are separable from the class of 186 DENV-2 and 4. On the other hand, α, V 0 , Z 0 , φ, π 1 , π 2 remain almost in the weak correlation regime with the viraemia for 187 all the serotypes. In row Fig 5B, Once the POMs have been constructed, we approach predicting the treatment for controlling the fever to the virtual 193 population of dengue patient models. As the total number of qualified models in the POMs is large (221 for DENV-1, 306 for 194 DENV-2, 93 for DENV-3, and 81 for DENV-4), we randomly choose 15% of the candidate models from the POMs of each 195 serotype for the control experiment. During the random selection, we draw the models from the POMs with a uniform 196 distribution and obtain 33,45, 13 and 12 models for DENV-1, DENV-2, DENV-3 and DENV-4, respectively. We could have 197 chosen the best 15% of the best fitted models as the candidates for control experiment, but those do not appear in every 198 domain of the POMs. In Fig 6, we present the viraemia, and DI particle levels before and after applying the control. For 199 DENV-1, the viraemia lasts until day 10 keeping the control on for the whole period in most of the cases, while in case of the 200 other serotypes the control shuts down approximately by day 8. The occurrence of the oscillatory peak in every few DENV-2 201 and DENV-3 models, pushes the control to higher dose although the viraemia cannot last beyond day 5.
202
The infected cellular dynamics also shows remarkable changes after the application of excess DI particles in the host 203 system (Fig 7) . The general trend before and after applying the control is observed in the C D cells, which is similar to that of 204 the DI particles, as the DI particles are the major reason to generate the pool of C D cells. A similar relation is observed 
In Fig 8, we show the distribution of the viraemia fold reduction with respect to the control expense for all the four serotypes. 214 Approximate monotonic increments are observed in R, with S for all the serotypes except DENV-2. For DENV-2, we find two 215 separable clusters; one lies in the same cluster as the other serotypes and the other cluster appears with a completely opposite 216 trend but at higher control expense.
217
Discussion
218
The two prime interests of this paper are to capture the inherent variability in dengue infected patient data through a 219 within-host model and predict efficient intervention to control dengue fever via administration of excess defective interfering 220 particles (DIPs). We present the method of population of models (POMs) to execute the first goal and a population of 221 bang-bang optimal control settings for the second aim. We show that the POMs not only capture the biomarker dataset but 222 also provides the range of variability for each cell-virus interaction and its association with the biomarker kinetics in 223 population and individual levels. A sub-population of the calibrated POMs are used with bang-bang control to reduce the 224 viraemias in significant orders. In that case, the fever cannot reach severe dengue and the DI particles do not stop replicating. 225 As per our findings, the antiviral property of the DI particles appears as a potential intervention strategy to attenuate the 226 patient viraemia significantly.
227
We construct four serotype-specific populations of within-host models for dengue against the variability in the biomarker 228 levels in blood samples of the admitted patients as reported [8] . The four POMs explore a range of patient-specific 229 9/16 parameters, those in different combinations, produce four populations of feasible dengue models within the range of the 230 experimental data. The calibration of the POMs helps us to discriminate and classify among the serotypes and inter-patient 231 variability through the parameter variability and sensitivity. The aim of this methodology is not to look at the dynamics of 232 isolated models in the population as any single model does not represent an individual. The aim is to incorporate variability 233 in the same model and observe the whole population of patients with similar symptoms.
234
The variability appears in the population of the viraemia load and corresponding antibody response due to the differences 235 in the patient-specific parameters. One of the crucial factors that drives this variability is the incubation period for an 236 individual model. We want to mention that we trace the variability of incubation periods of an individual model in terms of 237 the variability in viral load on day 0 of illness (V 0 ) and that efficiently fits with the calibration process. The dynamics of the 238 viraemia (V ) is directly dependent on δ, π 1 , π 2 for release after maturation of the infected C V to C V * and on the antibody 239 response (Z) for clearance. Indirectly, the rate of infection (k) also drives the viraemia. Amongst these parameters, δ is in 240 strong positive correlation with V , Z and D and that gradually leads to a flip as the viraemia dies with the days of illness, 241 but π 1 is weakly correlated all the time. The variability of highly correlated parameters stay within a narrow range and 242 calibrates tightly with the biomarker data, but weakly correlated parameters spread over wide ranges to generate models with 243 similar behavior (Fig 3 and 5) . the onset of the symptoms in case of DENV-2 and DENV-3 and it depends on the degree of infection (Fig 2) . Although, the 250 few relatively high peak heights in viraemia data for DENV-1 cannot be captured in our model.
251
Among the reported infections of the hospitalized patients in our model, most of the DENV-1 infected patients have 252 primary infection while the majority of the patients with the other serotypes are reported as secondary infection. A careful 253 observation of the POMs of the viraemia profiles enables us to find the growth rate of the viraemia for most of the models in, 254 with the DENV-2 and DENV-3 POMs growing faster than the others. We explain this rapid growth in terms of the antibody 255 dependent enhancement (ADE) that only occurs in secondary infection [6] . In case of primary infection, the immune response 256 is triggered very slowly and the viraemia is almost cleared when the response level is significant. On the other hand, the same 257 response for the secondary infection is very rapid and prominent. In the articles of Clapham et. al., two different within-host models for dengue infection have been presented for DENV-1 259 and DENV-2. They found variability in the rate of infection (k) only and that was used to discriminate between the ranges of 260 viraemia loads [20] . Later they have fitted another model with a direct and indirect effect of the antibody response through 261 free virus neutralization and infected cell death [19] . In this present article, we keep k and constant for each serotype and 262 included only the direct antibody response for virus particles (standard or defective) neutralization and the antibody response 263 is triggered by both of the free virus and free defective particles. The variability in the antibody response is captured by η 1 264 and η 2 and their contributions are reflected in the POMs. The greater the proliferation (η 1 ) rate varies, the more the 265 12/16 antibody plateau widens (Fig 2 and 3) . Notably, in the case of DENV-4, the spread for both of η 1 and η 2 are narrow. Again, 266 the strong negative correlation of η 1 with the viraemia does not appear to be significant in comparison with the case of the DI 267 particles and Z. This may explain the intensity of the triggered antibody response being more effective on V than D.
268
Another significant outcome of such a population level modeling approach is in the quantitative prediction of vaccination or 269 any kind of intervention strategy. We use an optimal bang-bang control approach to add excess DI particles in to the system 270 to reduce the viraemia. Previously, Rodrigues et. al. showed optimal control for dengue using vaccination compartment inside 271 an epidemic viewpoint [18] . But intervening individual human host models within a population has not been observed yet.
272
Furthermore, the naturally occurring defective interfering particles have not been utilized in dengue control before.
273
Bang-bang control is a prominent optimization tool in dynamical programming for linear systems and can be solved easily 274 using boundary value problem (BVP) solvers [32] . But a nonlinear two-point boundary value problem (TPBVP) such as our 275 present model cannot be solved directly with traditional solvers. We use the forward backward sweep method, where ODE 276 solvers are used twice: forward for the state equations and backward for the costate equations [33] . Then we update the 277 switching function(∂H/∂u) and control (u(t)) [34, 35] . In most of the cases, for such nonlinear models, nonlinear 278 programming is mostly used for calculating discontinuous controls. We use the same Pontryagin's minimum principle and 279 solve the discontinuous right hand side of the state and co-state equations. We note that this method needs many more 280 iterations than continuous control methods to converge. However, for models with strong non-linearity such as stiff and 281 oscillatory control problems, this method is reasonably efficient.
282
We perform the control experiment on a randomly chosen 15 per cent of models from the calibrated population of models 283 for each serotype. In Fig 6, the population of controls (POCs) profiles for the four serotypes are quite self-explanatory. As the 284 replication of the DI particles depend on the replicative machinery of the standard virus, the excess DI particles are rapidly 285 cleared out of the host system as soon as the control shuts down and viraemia is cleared. We ensure the amplitude of the 286 control, i.e., addition of excess DI particles, to be equivalent to the level of viraemia peak during computing the controls, 287 otherwise the amount of the DI particles are not sufficient to reduce the viraemia peak. Our aim is to keep the viral load 288 approximately below 10 8 but for DENV-2 and DENV-3 it is difficult to achieve that even after applying 10 11 of DI particles. 289 The reason behind this is the higher rates of virus replication (β and π 2 ) in DENV-2 and DENV-3 as mentioned before. In 290 the cases of DENV-1 and DENV-4, as soon as the DI particles start boosting, the viral load drops quickly, as DI particles 291 interfere in the virus replication. Very tiny persistent oscillations in the case of DENV-2 and DENV-3 in all the cell types and 292 viraemia also validates the same conclusions.
293
To examine the efficiency of the control experiment, we refer to the scatter plot in Fig 8 for the measured control expense 294 (A) and the corresponding reduction in viraemia (R). For DENV-1, DENV-3 and DENV-4, most of the models are in the left 295 half of the figure (i.e., A ≤ 10 3 ) while DENV-2 has many more models in the high A domain (i.e., A ≥ 10 3 ). In most of the 296 cases for DENV-1, the reduction (R) is higher than the other serotypes at low expense on control (A) and that makes the 297 control for DENV-1 as the most efficient. The present model predicts that large numbers of DI particles would be 298 administered to DENV patients to have any effect on viraemia as patients only become symptomatic and seek medical 299 assistance at the time of peak viraemia or soon after. The model also assumes that DI particles and wild type viruses are of 300 equal fitness when competing for replicative machinery within host cell. If, however, DI particles are interfering with 301 replication of wild type viruses by enhancing production of interferon or some other mediator, then a single DI 302 particle/genome may elicit a response in the host cell that interferes with the replication of large number of wild type viruses. 303 In addition, there exists no specific metric that may provide room to define the efficiency of the DI particles. A distribution 304 of DI particle with variability in their competitions with the virus particles for the replication and packaging can be modeled 305 to predict the efficiency of the DI particles through successive passages. Existing models and experiments with DI particles 306 assume the efficiency of the DI particles inversely proportional to their nucleotide lengths though the nucleotide lengths 307 cannot decide on DIP efficiency. A single cell stochastic model with distribution of DIPs and their evolutionary aspects may 308 open a new avenue to explore the DIP efficiency.
309
Despite the availability of real clinical data for the admitted patients and experimental success, the intra-host dengue virus 310 dynamics is not explored well. As a consequence, the virus transmission dynamics to mosquitoes is not clear. This paper 311 explores the variability regime of the intra-host DENV dynamics across a population of patients for the four DENV serotypes. 312 These POMs are able to predict the effective roles of the virus replication and subsequent immune response to determine the 313 within-host viraemia characteristics. For the same patients population, a human to mosquito transmission model is underway. 314 Those results may explore the quantitative analysis of infected patients turned into infectious and their infectiousness in terms 315 of the transmission. Addition of minimal amount of defective particles leads to significant reduction in the viraemia 316 characteristics reflecting the potential anti-viral property to be manifested in dengue control. 317 
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